FDA Inspection 1088122 — Robert Anderson
The FDA completed an inspection of Robert Anderson on April 12, 2019 in Omaha, NE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 12, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Omaha, NE (United States)
Additional Details
Clinical Investigator (CI)